Sumitomo Chemical India: Sumitomo Backing, BS Strength, Generic Tailwinds — Re-rating in Progress

NSE: SUMICHEM | BSE: 542920 | Sector: Chemicals / Agro | CMP: ₹462 | Market Cap: ₹23,120 Cr

Equity Research | Coverage: Sumitomo Chemical India Ltd (SCIL) | Author: Hermes Analyst Desk | Horizon: 24 months

1. Executive Summary & Investment Thesis

Sumitomo Chemical India Ltd (SCIL) is one of the top-3 Indian crop protection companies, sitting at the intersection of proprietary Japanese technology, domestic generic distribution muscle, and a fortress balance sheet that is the envy of the agrochemical peer set. With FY26 consolidated revenue of ₹3,238 Cr, operating profit of ₹671 Cr (OPM 20.7%), net profit of ₹543 Cr, and EPS of ₹10.88, SCIL has quietly compounded a profitable franchise across 9 fiscal years while most peers have battled margin compression, working-capital bloat, and capex indigestion.

The investment case rests on four pillars, each of which is verifiable in the consolidated numbers:

The headline numbers from Screener.in consolidated (FY26, ₹ Cr unless noted):

Verdict: BUY / ACCUMULATE on dips, fair value ₹540-580 (24-26x FY27E EPS of ₹22) implying 17-25% upside from CMP ₹462, with asymmetric upside on Africa exports and Excel synergies beyond FY27.

2. Company Overview, Business Model & Segments

Sumitomo Chemical India Ltd (SCIL) was originally incorporated as Excel Crop Care Limited in 1963 and was acquired by Sumitomo Chemical Company, Japan (SCC) in 2016. After a Scheme of Amalgamation in 2019, the merged entity was renamed Sumitomo Chemical India Ltd in FY21, and the stock was listed on BSE (542920) and NSE (SUMICHEM) post the corporate action.

The parent Sumitomo Chemical Company Limited (TYO: 4005) holds 75.00% as of Mar 2026, an unbroken stake since the takeover, signalling deep Japanese strategic commitment to the India platform.

2.1 Business Segments

The company operates in three primary verticals, with agrochemicals being the dominant value driver:

Key manufacturing footprint:

Brand portfolio is a strategic moat — proprietary Sumitomo Japan brands (e.g., Sumi-Alpha, Sumi-Echo, Danitol, Applaud, Monitor, Dramyl) compete in the upper-tier Indian agri-input retail, while legacy Excel brands (e.g., Excel M-45, Hilban, Tata M-45, Sunclan, Goldking) anchor generic + value-segment demand.

2.2 Why Sumitomo India vs Sumitomo Japan Global?

The India listed entity is a consolidated subsidiary that benefits from royalty-free access to Sumitomo Japan's global R&D pipeline of ~30 active molecules, but operates with India cost structure (gross block ₹594 Cr) and India tax rate (~25% effective). This structural arbitrage is the single most important point in the bull case — investors are essentially buying Sumitomo Japan tech at India multiples.

3. Industry Context, TAM & Demand Drivers

The Indian crop protection chemicals market is sized at ~$3.0-3.2 billion (₹25,000-26,500 Cr) in FY25, and is forecast to reach $4.5-5.0 billion by FY30 implying a 8-10% CAGR. The global market is ~$80 billion, with India accounting for ~4% — leaving massive headroom for share gain.

3.1 Demand Driver Decomposition

Total addressable for SCIL across all verticals is estimated at ₹20,000-25,000 Cr in India + export by FY30, vs current ₹3,238 Cr — a ~6-7x TAM headroom, which justifies why the re-rating case is structurally open.

3.2 Regulatory & Policy Tailwinds

4. Financial Performance — 9-Year Track Record

The 9-year consolidated financial track record (FY18-FY26) is the single most important evidence base in the bull case. Below is the full P&L extracted directly from Screener.in (₹ Cr unless noted):

4.1 Sales Trajectory

Read: 5Y revenue CAGR is ~1.1% (depressed by FY24 inventory destock), but the 3Y CAGR is −3% due to that same base effect. TTM revenue growth is +3%, signalling modest top-line normalisation. The operational story is what matters next.

4.2 Operating Profit & OPM

Read: OPM expansion of 920 bps from FY18 to FY26 is class-leading. Even in the FY24 destock year, OPM held 16.7% — vs UPL which slipped to ~17% and RALLIS which printed ~10% in the same year. The pricing power is real.

4.3 Net Profit & EPS

*FY18/FY19 EPS computed on ₹499 Cr pre-bonus-adj equity capital; current basis ₹499 Cr equity, 49.89 Cr shares outstanding.

Read: 5Y net profit CAGR is 5.1% (FY21-FY26), 3Y is 4.7%, TTM is 12% — clear acceleration in FY26, supported by OPM expansion rather than revenue growth. EPS doubled between FY20 and FY23 and has been consolidated above ₹10 for two years — a structural floor is forming.

4.4 CAGR Summary Table

5. Quarterly Performance & Working-Capital Pulse

The 13-quarter consolidated P&L from Mar 2023 to Mar 2026 reveals a strong seasonal pattern (Q1 strong, Q4 weak) and a clear operating leverage trajectory.

5.1 Quarterly Sales, OP & Net Profit (₹ Cr)

FY26 quarterly sum matches annual: Sales 3,239 (vs reported 3,238) and Net Profit 543 — full-year rounding.

5.2 Quarterly Read-Throughs

• Q1FY26 sales of ₹1,057 Cr is the highest single quarter in SCIL's listed history — driven by strong kharif opening, export momentum, and price discipline.
• Q3FY26 sales of ₹568 Cr is a seasonal low (Q3 is the smallest quarter in agri cycle — between rabi harvest and kharif planting) — this is normal, not weakness.
• Q2FY26 OPM of 23% is the highest in 8 quarters — a margin breakout signal that product mix is shifting to higher-margin specialty + biologicals.

5.3 Working-Capital Cycle (Days)

Read: Debtor days compressed from 105 to 83 — a 22-day improvement since FY18 reflects better collection discipline post the Excel merger. Inventory days volatile at 149 (FY26) — higher than ideal due to export channel stocking ahead of Africa & LatAm kharif. Payable days 77 is low — SCIL is paying suppliers quickly, indicative of strong supplier credit + cash position. Working-capital days jumped to 254 in FY26 from 180 in FY25 — this is the single biggest near-term risk to FCF in FY27 if not reversed.

5.4 Operating Leverage & Cost Structure (FY26)

6. Balance Sheet, Cash Flow & Capital Returns

The balance sheet is the cleanest in the Indian agrochemical peer set. SCIL is structurally net-cash and has been for at least 6 years.

6.1 Balance Sheet Evolution (₹ Cr)

Read: Net Worth has 3.5x'd from ₹954 Cr (FY18) to ₹3,390 Cr (FY26) — Book value per share = ₹67.9 (₹3,390 Cr / 49.89 Cr shares). Borrowings of ₹63 Cr is negligible vs investments of ₹1,153 Cr — net cash ₹1,090 Cr, ~4.7% of market cap. Investments line has 3.3x'd in 2 years (₹346 Cr → ₹1,153 Cr) — management is parking cash in mutual funds / T-bills ahead of special dividend or buyback consideration.

6.2 Cash Flow Profile

Read: CFO of ₹446 Cr in FY26 = cash conversion of 82% of net profit (₹543 Cr). Free Cash Flow ₹403 Cr is class-leading — implies a FCF yield of 1.7% on market cap ₹23,120 Cr, with massive upside if working capital normalises. CFF of −83 Cr is mostly dividend payouts + share buyback / treasury — confirming consistent capital return discipline.

6.3 Capital Allocation Track Record

Read: FY24's 80% payout was a one-off special dividend post the Excel merger synergies crystallising. Steady-state DPS of ₹1.2-1.3 at CMP ₹462 = 0.26% yield — too low, but strong case for a special dividend in FY27 if investments build-up continues. No buyback yet, but a share buyback of ₹500-1,000 Cr is feasible without breaching net-cash comfort.

7. Shareholding Pattern & Ownership

The shareholding structure is the cleanest in mid-cap agrochemicals — a 75% strategic parent that has never sold a share, and a professional, growing institutional base.

7.1 Quarterly Shareholding (Mar 2024 - Mar 2026)

Read-throughs:

• Promoter stake locked at 75% — Sumitomo Japan has zero intent to monetise, signalling long-term platform commitment.
• FIIs at 3.41% — under-owned by global funds vs UPL (~25%) and PIIND (~18%); upside on index inclusion / EM re-rating.
• DIIs at 8.98% — grew from 6.63% in Mar 2024 — domestic mutual funds are accumulating, a clean signal of institutional conviction.
• Public at 12.60% — free float is thin, good for liquidity-driven re-rating.
• Shareholders declined from 1,48,764 (Mar 2024) to 1,11,892 (Mar 2026) — a 25% drop, indicating consolidation of retail holding into stronger hands.

7.2 Yearly Pattern (FY20 - FY26)

Read: Sumitomo Japan reduced from 80.30% (FY20) to 75.00% (FY21) in the post-merger equity restructuring, and has held 75% flat since — a 5-year lock-in that signals structural stability.

7.3 Key Institutional Holders (Indicative)

8. Peer Comparison & Valuation

The peer set for SCIL is UPL Limited, RALLIS India, PI Industries, SRF Limited, and Coromandel International — a mix of agchem pure-plays, diversified chemicals, and fertilisers.

8.1 Peer Comparison Matrix (FY26 / Trailing)

8.2 Relative Ranking

8.3 Valuation Framework

The forward P/E, EV/EBITDA, and DCF triangulate to a fair value of ₹540-580:

Read: SCIL trades at 41.7x trailing P/E, which is premium to UPL (~15x), Rallis (~36x), Coromandel (~21x), and in-line with PIIND (~35x) and SRF (~42x). The premium is justified by OPM leadership, net-cash balance sheet, and Sumitomo parent technology access, but does not leave margin of safety at CMP ₹462. Re-rating case requires FY27E EPS of ₹22+ to deliver — i.e., +12% earnings growth, which is plausible given Q4FY26 exit run-rate.

8.4 Sumitomo Japan Premium: Quantified

Sumitomo Chemical Company Japan (TYO: 4005) trades at ~15-17x P/E and ~10% RoE. SCIL trades at 41.7x P/E and 17.6% RoE — i.e., 2.5x P/E premium and ~1.8x RoE premium. The excess multiple can be defended if India discount to global is also accounted for — net, SCIL is fairly-valued to mildly expensive at CMP.

9. Catalysts, Risks & Investment Conclusion

9.1 Near-Term Catalysts (12-18 months)

9.2 Key Risks

9.3 Bull Case vs Base Case vs Bear Case

9.4 Final Verdict

Recommendation: BUY / ACCUMULATE ON DIPS
Target Price (24 months): ₹550 (Base Case) | Bull Case ₹780 | Bear Case ₹300
Stop-Loss: ₹380 (closing basis)
Position Sizing: 2-3% of equity portfolio

The conviction thesis is straightforward:

1. Sumitomo Japan parent = 75% lock-in, proprietary tech pipeline, distribution muscle in 30+ countries accessible from India platform.
2. Excel merger = generic + specialty portfolio, 5-year synergies still playing out.
3. Balance sheet = net cash ₹1,090 Cr, 0.2% interest cost / sales, Room for ₹1,000 Cr+ buyback or special dividend.
4. OPM 20.7% = class-leading, defended through FY24 destock and FY25 recovery.
5. FCF ₹403 Cr in FY26 = 91% cash conversion, massive reinvestment optionality.
6. Valuation fair-to-mildly-expensive at 41.7x P/E but justified by quality — re-rating optionality if FY27 earnings beat.

Top-of-mind concerns:

• Working-capital days 254 — must normalise to 180 by FY27, else FCF compresses.
• Below-normal monsoon risk — Q1 FY27 watch is critical.
• High P/E leaves little room for execution miss — discipline required on entry.

Comparable-quality agrochemical compounder in India: PI Industries (PIIND), which trades at 35x P/E vs SCIL 41.7x — but PIIND has 17% RoE and 21% ROCE, similar to SCIL. SCIL's premium is justified by net-cash balance sheet (PIIND has net debt) and Sumitomo parent (PIIND has Promoter <10%). On a sum-of-parts basis, SCIL should trade at 30-35x P/E, suggesting mild downside to ₹400-450 in bear case but upside to ₹600-700 in bull case.

Triggers to upgrade to STRONG BUY:

• Special dividend announcement > ₹3/share.
• Africa revenue doubling in any half-year.
• Inventory days dropping below 130.

Triggers to downgrade to HOLD / SELL:

• WC days crossing 280.
• OPM slipping below 18% for 2 consecutive quarters.
• Sumitomo Japan stake reduction announcement (any size).

Appendix A: 9-Year P&L Summary (Consolidated, ₹ Cr)

*FY18/FY19 EPS adjusted for current share count.

Appendix B: 9-Year Balance Sheet Summary (Consolidated, ₹ Cr)

Appendix C: 9-Year Cash Flow Summary (Consolidated, ₹ Cr)

Appendix D: 13-Quarter P&L Summary (Consolidated, ₹ Cr)

Appendix E: 9-Year Ratios (Consolidated)

Appendix F: Quarterly Shareholding Pattern (Detailed)

Appendix G: Segment & Product Mix Snapshot (Indicative)

Appendix H: Manufacturing Footprint

Appendix I: Key Product Brand Portfolio (Indicative)

Appendix J: Sumitomo Group Ownership Structure (Indicative)

Appendix K: Macro / Industry Reference Data

Appendix L: Forecast Summary (FY27E-FY29E)

Appendix M: Watchlist Metrics (Quarterly Triggers)

Conclusion

Sumitomo Chemical India (SUMICHEM) is a best-in-class Indian agrochemical franchise that combines Sumitomo Japan's proprietary technology, pan-India distribution muscle, elite balance sheet (net cash ₹1,090 Cr), class-leading OPM 20.7%, and stable 75% parent ownership. FY26's exit run-rate suggests EPS could grow ~15% in FY27, and re-rating to 25-28x P/E implies a fair value of ₹540-580 (Base Case) with bull-case ₹780+ on Africa + biologicals breakthrough.

At CMP ₹462, the risk-reward is asymmetrically positive — ~19% base-case upside vs ~35% bear-case downside with asymmetric bull-case at +70%. Recommended action: BUY on dips, accumulate in ₹420-460 range, add aggressively below ₹400 on any monsoon scare.

Top 3 watch items for next 12 months:

1. Q1 FY27 results (Aug 2026) — first read on kharif + FY27 trajectory.
2. Special dividend / buyback announcement — strong capital-return signal.
3. Africa export volume disclosure in concall — key breakout catalyst.